Solana R P, Gennings C, Carter W H, Anderson D, Lennox W J, Carchman R A, Harris L W
U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland 21010-5425.
Fundam Appl Toxicol. 1990 Nov;15(4):814-9. doi: 10.1016/0272-0590(90)90197-r.
Recent studies have shown that pretreatment with either pyridostigmine (PYR) or physostigmine (PHY) followed by atropine-oxime therapy is very effective in reducing the lethality of nerve agents. The therapeutic efficacy of a PHY and PYR combination pretreatment was evaluated in guinea pigs challenged with two LD50s of soman. Endpoints measured were percentage of acetylcholinesterase inhibition induced by the pretreatment and survival up to 24 hr postchallenge. Response surface methodology was employed to describe the relationship between each endpoint and the pretreatment combination. Although both carbamates contributed to blood acetylcholinesterase inhibition, PHY alone protected as well as the optimal dose of the combination.
最近的研究表明,先用吡啶斯的明(PYR)或毒扁豆碱(PHY)预处理,然后进行阿托品肟治疗,在降低神经毒剂的致死率方面非常有效。在接受两个梭曼半数致死剂量攻击的豚鼠中评估了PHY和PYR联合预处理的治疗效果。测量的终点指标为预处理引起的乙酰胆碱酯酶抑制百分比以及攻击后24小时内的存活率。采用响应面法描述每个终点指标与预处理组合之间的关系。虽然两种氨基甲酸酯都有助于抑制血液中的乙酰胆碱酯酶,但单独使用PHY的保护效果与组合的最佳剂量相同。